Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A physician is reviewing the laboratory results of a 64-year-old woman who had blood drawn earlier in the day for routine monitoring. The patient has a history of rheumatic heart disease and underwent a mechanical mitral valve replacement four years ago. She is maintained on chronic warfarin therapy. Three days ago, she was evaluated at an urgent care clinic for dysuria and was prescribed a short course of trimethoprim-sulfamethoxazole. During a subsequent telephone encounter, the patient reports feeling well and denies any bruising, bleeding gums, epistaxis, or dark stools. Her target international normalized ratio (INR) is 2.5 to 3.5. Today, her INR is reported as 7.2. Which of the following is the most appropriate next step in the management of this patient's anticoagulation?

  1. A
    Hold the warfarin and administer intravenous fresh frozen plasma
  2. B
    Hold the warfarin and administer oral phytonadione
  3. Hold the warfarin, recheck the international normalized ratio in 24 to 48 hours, and resume at a lower doseCevap
  4. D
    Discontinue the warfarin and initiate apixaban
  5. E
    Continue the current warfarin dose and discontinue the trimethoprim-sulfamethoxazole

Cevap

Hold the warfarin, recheck the international normalized ratio in 24 to 48 hours, and resume at a lower dose
The patient presents with a supratherapeutic INR of 7.2, likely secondary to a pharmacokinetic drug interaction between her chronic warfarin therapy and a recently initiated course of trimethoprim-sulfamethoxazole. Trimethoprim-sulfamethoxazole inhibits the cytochrome P450 2C9 (CYP2C9) enzyme, reducing the metabolism of warfarin and prolonging its anticoagulant effect. According to current consensus guidelines for the management of supratherapeutic INR, if a patient's INR is between 4.5 and 10.0 and there is no evidence of bleeding, the most appropriate management is to withhold the next one to two doses of warfarin, monitor the INR closely, and resume therapy at a lower, adjusted dose once the INR returns to the therapeutic range. Routine administration of vitamin K (phytonadione) is not recommended in this scenario because it does not improve clinical outcomes and can unnecessarily complicate re-anticoagulation.

Adım Adım Çözüm

1
Identify the patient's clinical status and laboratory abnormality.
The patient is asymptomatic with no signs of bleeding, but has a supratherapeutic INR of 7.2.
Determining the presence or absence of active bleeding is the critical first step in triaging the urgency of anticoagulation reversal.
2
Determine the etiology of the abnormal laboratory finding.
The elevated INR is due to a pharmacokinetic drug-drug interaction between warfarin and the recently prescribed trimethoprim-sulfamethoxazole.
Trimethoprim-sulfamethoxazole is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing the more active S-enantiomer of warfarin, leading to rapid accumulation and increased bleeding risk.
3
Apply consensus guidelines for managing a supratherapeutic INR without bleeding.
The correct management for an INR between 4.5 and 10.0 without bleeding is to hold the next 1-2 doses of warfarin.
Routine use of vitamin K is not recommended in this specific range for asymptomatic patients, as it does not reduce the incidence of bleeding events but does make achieving therapeutic anticoagulation more difficult afterward.

Anahtar Kavram

Management of asymptomatic supratherapeutic INR (4.5 to 10.0) involves withholding warfarin doses without routine administration of vitamin K.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru